Scientific, Regulatory and Strategic Consulting for Biotech. Track record of 50+ INDs, 300+ GLP toxicology studies. Board-certified toxicologist in the US and EU.
BiotechGoChicago1.jpg

Into the IND and Beyond

Toxicology and regulatory consulting for emerging biotech.

Track record across 50+ drug development programs.

China CRO outsourcing, GLP audits and monitoring.

Tailored Drug Development Strategy for Emerging Biotech

I provide senior-level advisory support for early-stage drug development, with emphasis on toxicology, nonclinical strategy, regulatory positioning, China CRO execution, virtual R&D operations, and program management. With hands-on experience from over 50 development programs and 300+ GLP toxicology studies, I support modalities from small molecules, peptides and protein degraders to RNA therapeutics and biologics (antibodies, recombinant proteins, ADCs, oncolytic viruses), across oncology, CNS, inflammation, endocrinology, and rare diseases.

I work closely with biotech founders and teams to reach key regulatory milestones such as IND submissions and clinical proof of concept, while keeping operations lean and timelines accelerated. My approach emphasizes efficiency and strategic planning, helping clients skip studies they don’t need and avoid excess R&D spend.

Based in Beijing, I have nearly two decades of hands-on operational experience with major CROs in China, including WuXi AppTec, Pharmaron, JOINN, and Medicilon. Well-structured China-based programs commonly provide substantial cost and timeline advantages relative to US execution, particularly for technically complex or non-human-primate studies. Sponsors often see two- to three-fold lower costs and shorter timelines when programs are well managed.

Beyond vendor selection, I am directly involved in CRO qualification, study oversight, audits, protocol optimization, and monitoring, supported by appropriate documentation and regulatory-aware practices. This structure is designed to reduce both scientific and compliance risk while ensuring that outsourced studies remain aligned with global regulatory expectations. I have no financial relationship with the CROs named on this site.

 

Services


IND-enabling services

I help early-stage teams reach submission with disciplined, cost-effective, regulator-aligned nonclinical plans. I have contributed to more than 50 successful IND, IMPD, and CTA submissions across a broad range of modalities, including small molecules, biologics, recombinant proteins, peptides, and oligonucleotide-based therapeutics, and therapeutic areas such as oncology, CNS, GI, inflammation, and rare diseases. My work focuses on regulatory strategy, nonclinical data package planning, and preparation of key electronic Common Technical Document (eCTD) sections to ensure submission readiness and facilitate regulatory review.


STRATEGIC CONSulting and program management

I offer hands-on strategic guidance and program leadership for early-stage biotech companies, based on experience advancing assets from early financing through first-in-human studies and signal-generating Phase 1/2 trials. My approach is tailored to each program’s stage, scientific characteristics, and risk profile, with focus on defining and achieving value-driving milestones such as IND submission and clinical proof of concept. I support clients in navigating complex development decisions, prioritizing critical activities, and optimizing timelines, budgets, and operational structures to maintain program momentum.



toxicology AND REGULATORY SUPPORT

As a board-certified toxicologist (US and EU) with 25 years of experience, I provide expert support across nonclinical safety strategy, GLP toxicology, and regulatory risk assessment. I have designed, monitored, and interpreted more than 300 GLP toxicology studies and regularly advise on study design, data interpretation, and the implications of nonclinical findings. My experience includes direct interaction with regulatory authorities such as the US FDA, China NMPA, and Australia TGA, including support for pre-IND and other key meetings, as well as strategic input on development pathways and regulatory designations. The objective is a scientifically sound, defensible path to first-in-human studies.


China CRO Selection, Auditing and Monitoring

I am personally involved throughout every engagement, from CRO identification, bid evaluation, and protocol review to study oversight, milestone tracking, and documentation. I provide independent CRO selection, GLP auditing, and nonclinical study monitoring across China and the broader APAC region. Based in Beijing, I bring nearly two decades of direct operational experience working with leading CROs in China. Services include GLP and quality system audits, on-site monitoring, data and report review, and expert input on study conduct and interpretation, ensuring outsourced programs remain aligned with global regulatory expectations.


 
 
 

 
 

Contact

Use the form below to contact me. You can also email me: harri @ [this domain].